



**Dr. Reddy's Laboratories Ltd.**

8-2-337, Road No. 3, Banjara Hills  
Hyderabad – 500 034, Telangana, India

CIN: L85195TG1984PLC004507

Tel: + 91 40 4900 2900

Fax: + 91 40 4900 2999

Email: [mail@drreddys.com](mailto:mail@drreddys.com)

Web: [www.drreddys.com](http://www.drreddys.com)

January 10, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

**Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Following our intimation dated September 13, 2025 regarding the Pre-Approval Inspection (PAI) by United States Food & Drug Administration (USFDA) at our biologics manufacturing facility in Bachupally, Hyderabad, we wish to inform you that we have received a Post- Application Action Letter (PAAL) from the USFDA in relation to the response submitted.

The company will work closely with the USFDA and is committed to addressing the queries specified in the PAAL.

This is for your information and records.

Thanking you,

Yours faithfully,

For **Dr. Reddy's Laboratories Limited**

**K Randhir Singh**

*Company Secretary, Compliance Officer & Head-CSR*